MedTrace Logo

HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)

NCT02013310 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2015-12-30

No results posted yet for this study

Summary

This is a Phase 2 randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of HT-0712 in improving memory and cognitive performance in subjects with Age-Associated Memory Impairment (AAMI)

Conditions

  • Age-Associated Memory Impairment (AAMI)

Interventions

DRUG

HT-0712

DRUG

Placebo

Sponsors & Collaborators

  • Dart NeuroScience, LLC

    lead INDUSTRY

Principal Investigators

  • Philip Perera, MD · Dart NeuroScience, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02013310 on ClinicalTrials.gov